| Literature DB >> 29326951 |
Mingpu Qi1,2, Qiankun Wang1,2, Shengtao Tong2, Gang Zhao1,2, Changmin Hu2, Yingyu Chen2, Xiang Li3, Wanji Yang4,5, Yuchen Zhao4,5, Sara Platto2, Robertson Ian Duncan1,2,6, Jianguo Chen2, Huanchun Chen1,2, Aizhen Guo1,2,6.
Abstract
Fecal samples (n = 76) were collected from 38 snub-nosed monkeys (Rhinopithecus roxellana) in Shennongjia National Nature Reserve (China) and examined for the presence of enteropathogenic Escherichia coli (EPEC). The 56 samples originated from 30 free-ranging monkeys on the reserve and 20 samples from 8 captive monkeys that were previously rescued and kept at the research center. Eight diarrhea samples were collected from four of the eight captive monkeys (two samples from each monkey), and two EPEC strains (2.6%) (95% confidence interval 0.3-9.2%) were isolated from two fecal samples from two diarrheic monkeys. Both strains belonged to serotype O98 and phylogenetic group D (TspE4C2+, ChuA+). The virulence gene detection identified these strains as an atypical EPEC (aEPEC) (bfpB - , stx1 - , and stx2-) with the subtype eae+, escV+, and intiminβ+. These strains were highly sensitive to all the antibiotics tested. The lethal dose 50% of the two isolates in Kunming mice was 7.40 × 108 CFU/0.2 mL and 2.40 × 108 CFU/0.2 mL, respectively, indicating low virulence. Based on the report that this serotype had been isolated from some other non-human animals and humans with diarrhea, the first identification of aEPEC O98 strains and their drug resistance profile in R. roxellana is of ecological significance for disease control in this endangered species.Entities:
Keywords: Rhinopithecus roxellana; diarrhea; enteropathogenic Escherichia coli; non-human primates; virulence
Year: 2017 PMID: 29326951 PMCID: PMC5733351 DOI: 10.3389/fvets.2017.00217
Source DB: PubMed Journal: Front Vet Sci ISSN: 2297-1769
Figure 1Monkeys sampled in this study. (A) The monkeys from a one-male and multi-female unit waiting for food in the tree before feeding time; (B) monkeys fed with different food, which varies with the seasons; (C) the monkeys kept in the cage which is located in an open area.
Information on golden snub-nosed monkeys with fecal samples.
| Sampling time | Location | Monkey ID | Sex | Age | Health status | Number of samples collected |
|---|---|---|---|---|---|---|
| July–September 2013 | Dalongtan | BT | M | Adult | H | 2 |
| DD1 | F | Adult | H | 2 | ||
| HH1 | F | Adult | H | 2 | ||
| YY1 | F | Adult | H | 2 | ||
| TJ | F | Sub-adult | H | 1 | ||
| DWB | F | Adult | H | 2 | ||
| NN | M | Adult | H | 2 | ||
| XB1 | F | Adult | H | 2 | ||
| XH | F | Adult | H | 2 | ||
| HH2 | F | Adult | H | 2 | ||
| ME | F | Sub-adult | H | 2 | ||
| XY | F | Sub-adult | H | 2 | ||
| XB2 | M | Adult | H | 2 | ||
| LN | F | Adult | H | 2 | ||
| GG | F | Adult | H | 2 | ||
| FF | M | Sub-adult | H | 1 | ||
| YZ | F | Sub-adult | H | 1 | ||
| YE | F | Sub-adult | H | 1 | ||
| XXL | M | Sub-adult | H | 1 | ||
| YJ | M | Sub-adult | H | 2 | ||
| Xiaolongtan | BB2 | M | Adult | D | 2 | |
| QQ1 | F | Adult | H | 3 | ||
| QQ2 | M | Adult | H | 3 | ||
| HH3 | F | Adult | D | 2 | ||
| YY2 | F | Adult | D | 2 | ||
| TT | M | Adult | H | 3 | ||
| JJ | F | Sub-adult | D | 2 | ||
| LL2 | F | Sub-adult | H | 3 | ||
| March 2014 | Dalongtan | XX | M | Adult | H | 2 |
| BB1 | F | Adult | H | 2 | ||
| HHE | F | Adult | H | 2 | ||
| LL1 | F | Adult | H | 2 | ||
| SB | F | Sub-adult | H | 2 | ||
| DW | M | Sub-adult | H | 2 | ||
| XHT | M | Adult | H | 3 | ||
| WY | M | Adult | H | 2 | ||
| YH | M | Adult | H | 2 | ||
| JW | M | Sub-adult | H | 2 | ||
| Total | 76 | |||||
adult, more than 5 years; D, diarrhea; H, healthy; sub-adult, 2–4 years.
Primer sequences, annealing temperatures, and sizes of amplified fragments from selected genes of the target pathogens.
| Primers | Sequence(5′–3′) | Product size (bp) | Anneal temperature (°C) | Pathovar | Reference |
|---|---|---|---|---|---|
| GAGTAATGTCGGGGCATTCA | 152 | 55 | Clermont et al. ( | ||
| CGCGCCAACAAAGTATTACG | |||||
| GACGAACCAACGGTCAGGAT | 279 | 55 | Clermont et al. ( | ||
| TGCCGCCAGTACCAAAGACA | |||||
| TGAAGTGTCAGGAGACGCTG | 211 | 55 | Clermont et al. ( | ||
| ATGGAGAATGCGTTCCTCAAC | |||||
| TCAATGCAGTTCCGTTATCAGTT | 482 | 58 | Vidal et al. ( | ||
| GTAAAGTCCGTTACCCCAACCTG | |||||
| ATTCTGGCTCTCTTCTTCTTTATGGCTG | 544 | 62 | Antikainen et al. ( | ||
| CGTCCCCTTTTACAAACTTCATCGC | |||||
| GACACCTCATTGCTGAAGTCG | 910 | 60 | Antikainen et al. ( | ||
| CCAGAACACCTCCGTTATGC | |||||
| CCTTAGGTAAGTTAAGT | 558 | 52 | EPEC | Adu-Bobie et al. ( | |
| TAAGGATTTTGGGACCC | 562 | 50 | |||
| ACAAACTTTGGGATGTTC | 562 | 58 | |||
| TACGGATTTTGGGGCAT | 563 | 52 | |||
| TTTATGTGCAGCCCCCCAT | |||||
| CCCGAATTCGGCACAAGCATAAGC | 2,608 | 68 | Oswald et al. ( | ||
| AGCTCACTCGTAGATGACGGCAAGCG | |||||
| CGATGTTACGGTTTGTTACTGTGACAGC | 244 | 62 | Müller et al. ( | ||
| AATGCCACGCTTCCCAGAATTG | EHEC | ||||
| GTTTTGACCATCTTCGTCTGATTATTGAG | 324 | 61 | Müller et al. ( | ||
| AGCGTAAGGCTTCTGCTGTGAC | |||||
| GAACAGGAGGTTTCTGCGTTAGGTG | 655 | 60 | Müller et al. ( | ||
| CTTTCAATGGCTTTTTTTTGGGAGTC | |||||
| CCTCTTTTAGYCAGACARCTGAATCASTTG | 157 | 62 | ETEC | Müller et al. ( | |
| CAGGCAGGATTACAACAAAGTTCACAG | |||||
| TGTCTTTTTCACCTTTCGCTC | 171 | 58 | Müller et al. ( | ||
| CGGTACAAGCAGGATTACAACAC | |||||
| CGATCAAGAATCCCTAACAGAAGAATCAC | 766 | 62 | Müller et al. ( | ||
| CGATAGATGGCGAGAAATTATATCCCG | EIEC | ||||
| TGCCATCAACACAGTATATCCG | 102 | 58 | Antikainen et al. ( | ||
| ACGGCTTTGTAGTCCTTCCAT | |||||
| ACGCAGAGTTGCCTGATAAAG | 400 | 58 | EAEC | Antikainen et al. ( | |
| AATACAGAATCGTCAGCATCAGC | |||||
| AAATGTCAGTGAACCGACGATTGG | 1,111 | 60 | Antikainen et al. ( | ||
| AGCCGTTTCCGCAGAAGCC | |||||
| TATGCCCCATCGTGTAGTCAGAAC | 312 | 58 | Park et al. ( | ||
| TGCGGCTGGATCACCTCCTT | |||||
| AGCTCAGGCAATGAAACTTTGAC | 618 | 58 | Vidal et al. ( | ||
| TGGGCTTGATATTCCGATAAGTC | |||||
| CTCGGCACGTTTTAATAGTCTGG | 933 | 58 | Vidal et al. ( | ||
| GTGGAGAGCTGAAGTTTCTCTGC |
EAEC, enteroaggregative Escherichia coli; EHEC, enterohemorrhagic Escherichia coli; EIEC, enteroinvasive Escherichia coli; EPEC, enteropathogenic Escherichia coli; ETEC, enterotoxigenic Escherichia coli.
Figure 2Genotyping and serotyping of Escherichia coli isolates. (A) The triplex PCR specific for E. coli phylogenetic groups. (M) DNA ladder (DL2000); lanes 1–3: PCR products with primers specific to the genes yjaA, ChuA, and TspEC2, using the template of strain 1; lanes 4–6: PCR products with primers specific to the genes yjaA, ChuA, and TspEC2, using the template of strain 2. (B) The strains were typed by the slide agglutination test with standard antisera against all antigens of enteropathogenic E. coli (EPEC), enterotoxigenic E. coli (ETEC), enterohemorrhagic E. coli (EHEC), enteroinvasive E. coli (EIEC), enteroaggregative E. coli (EAEC), and diffuse-adhering E. coli (DAEC) of O1–O163. The left was O98 positive, shown by the apparent white agglutinating clusters, while the right was negative.
Figure 3Subgenotyping of Escherichia coli isolates based on the virulence genes. (A) PCR analyses of virulence factors. M: DNA ladder (DL2000); lanes 1–5: PCR products with primers specific to the genes eae, escV, bfpB, stx1, and stx2, using the template of strain 1; lanes 6–10: PCR products with primers specific to the genes eae, escV, bfpB, stx1, and stx2, using the template of strain 2; lane 11: negative. (B) PCR analysis of intimin subtypes. M: DNA ladder (DL2000); lanes 1–5: PCR products with primers specific to intimin α, intimin β, intimin γ, intimin δ, and intimin ε, using the template of strain 1; lanes 6–10: PCR products with primers specific to intimin α, intimin β, intimin γ, intimin δ, and intimin ε, using the template of strain 2; lane 11: negative control.
Antibiotic susceptibility testing of atypical EPEC isolates.
| Category | Antibiotics (128 µg/mL) | MIC (μg/mL)/interpretation | |
|---|---|---|---|
| Strain 1 | Strain 2 | ||
| Aminoglycosides | Amikacin | ≤2/S | ≤2/S |
| Gentamicin | ≤1/S | ≤1/S | |
| Tobramycin | ≤1/S | ≤1/S | |
| Cephalosporins | Cefepime | ≤1/S | ≤1/S |
| Cefotetan | ≤4/S | ≤4/S | |
| Ceftazidime | ≤1/S | ≤1/S | |
| Ceftriaxone | ≤1/S | ≤1/S | |
| Cephazolin | ≤2/S | ≤2/S | |
| β-lactams | Ampicillin | ≤2/S | ≤2/S |
| Aztreonam | ≤1/S | ≤1/S | |
| Meropenem | ≤1/S | ≤1/S | |
| Fluoroquinolones | Ciprofloxacin | ≤0.25/S | ≤0.25/S |
| Levofloxacin | ≤0.25/S | ≤0.25/S | |
| Penicillins | Imipenem | ≤1/S | ≤1/S |
| Piperacillin | ≤4/S | ≤4/S | |
| Sulfonamide | Cotrimoxazol | ≤20/S | ≤20/S |
EPEC, enteropathogenic Escherichia coli; S, sensitive.